[go: up one dir, main page]

PT1781662E - Inibidores de rna polimerase dependendte de rna do vírus da hepatitie c e composições e tratamentos usando os mesmos - Google Patents

Inibidores de rna polimerase dependendte de rna do vírus da hepatitie c e composições e tratamentos usando os mesmos Download PDF

Info

Publication number
PT1781662E
PT1781662E PT05775853T PT05775853T PT1781662E PT 1781662 E PT1781662 E PT 1781662E PT 05775853 T PT05775853 T PT 05775853T PT 05775853 T PT05775853 T PT 05775853T PT 1781662 E PT1781662 E PT 1781662E
Authority
PT
Portugal
Prior art keywords
hepatitis
treatments
inhibitors
compositions
same
Prior art date
Application number
PT05775853T
Other languages
English (en)
Inventor
Javier Gonzalez
Tanya Michelle Jewell
Hui Li
Angelica Linton
John Howard Tatlock
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PT1781662E publication Critical patent/PT1781662E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrane Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT05775853T 2004-08-18 2005-08-05 Inibidores de rna polimerase dependendte de rna do vírus da hepatitie c e composições e tratamentos usando os mesmos PT1781662E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60261804P 2004-08-18 2004-08-18

Publications (1)

Publication Number Publication Date
PT1781662E true PT1781662E (pt) 2011-07-01

Family

ID=35429645

Family Applications (1)

Application Number Title Priority Date Filing Date
PT05775853T PT1781662E (pt) 2004-08-18 2005-08-05 Inibidores de rna polimerase dependendte de rna do vírus da hepatitie c e composições e tratamentos usando os mesmos

Country Status (42)

Country Link
US (3) US7151105B2 (pt)
EP (1) EP1781662B1 (pt)
JP (1) JP4372195B2 (pt)
KR (1) KR100851178B1 (pt)
CN (2) CN101006092B (pt)
AP (1) AP2313A (pt)
AR (1) AR050699A1 (pt)
AT (1) ATE506364T1 (pt)
AU (1) AU2005273619B2 (pt)
BR (1) BRPI0514425A (pt)
CA (1) CA2577525C (pt)
CR (2) CR8935A (pt)
CY (1) CY1111480T1 (pt)
DE (1) DE602005027580D1 (pt)
DK (1) DK1781662T3 (pt)
EA (1) EA012605B1 (pt)
EC (1) ECSP077264A (pt)
ES (1) ES2361845T3 (pt)
GE (2) GEP20115305B (pt)
GT (1) GT200500221A (pt)
HN (1) HN2005000449A (pt)
HR (1) HRP20110458T1 (pt)
IL (2) IL180933A (pt)
MA (1) MA28803B1 (pt)
MX (1) MX2007001527A (pt)
MY (1) MY146123A (pt)
NI (1) NI200700043A (pt)
NL (1) NL1029755C2 (pt)
NO (1) NO20071274L (pt)
NZ (1) NZ552874A (pt)
PE (1) PE20060677A1 (pt)
PL (1) PL1781662T3 (pt)
PT (1) PT1781662E (pt)
RS (1) RS51794B (pt)
SI (1) SI1781662T1 (pt)
SV (1) SV2007002202A (pt)
TN (1) TNSN07066A1 (pt)
TW (1) TWI376379B (pt)
UA (1) UA88909C2 (pt)
UY (1) UY29068A1 (pt)
WO (1) WO2006018725A1 (pt)
ZA (1) ZA200700779B (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4372195B2 (ja) * 2004-08-18 2009-11-25 ファイザー・インク Ｃ型肝炎ウイルスｒｎａ依存性ｒｎａポリメラーゼの阻害剤、並びにそれを使用する組成物及び治療
BRPI0615016A2 (pt) 2005-08-24 2011-05-03 Pfizer compostos inibidores de hcv polimerase, métodos para prepará-los e forma cristalina
CN102872461A (zh) 2007-05-04 2013-01-16 弗特克斯药品有限公司 用于治疗hcv感染的组合治疗
EP2008996A1 (en) * 2007-06-27 2008-12-31 Syngeta Participations AG Process for the production of pyrazoles
CN102083852A (zh) 2008-06-06 2011-06-01 西尼克斯公司 环孢菌素类似物及其在治疗hcv感染中的应用
CN104530048B (zh) 2008-08-11 2016-09-14 葛兰素史密丝克莱恩有限责任公司 腺嘌呤衍生物
JP2011530562A (ja) 2008-08-11 2011-12-22 グラクソスミスクライン エルエルシー アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
BR112012010110A2 (pt) 2009-10-30 2019-09-24 Boehringer Ingelheim Int regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina
EP2325173A1 (de) 2009-11-19 2011-05-25 Bayer CropScience AG Verfahren zum Herstellen von 5-Fluor-1-alkyl-3-fluoralkyl-1H-pyrazol-4-carbonsäurechloriden
PH12012501216A1 (en) * 2009-12-18 2012-11-05 Boehringer Ingelheim Int Hcv combination therapy
JP2013519644A (ja) 2010-02-10 2013-05-30 グラクソスミスクライン エルエルシー プリン誘導体およびそれらの薬学的使用
CA2786973C (en) 2010-02-10 2018-04-10 Robert Hermann Gibbon 6-amino-2-{[(1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate
CN102906073B (zh) 2010-05-20 2015-11-25 拜耳知识产权有限责任公司 1-烷基-3-二氟甲基-5-羟基吡唑的制备方法
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
FR2972452B1 (fr) * 2011-03-09 2013-03-15 Rhodia Operations Procede de preparation du difluoroacetonitrile et de ses derives
WO2013171134A1 (de) 2012-05-14 2013-11-21 Bayer Cropscience Ag Verfahren zum herstellen von 1-alkyl-3-fluoralkyl-1h-pyrazol-4-carbonsäurechloriden
WO2014081878A2 (en) 2012-11-21 2014-05-30 Stategics, Inc. Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival
MX361768B (es) 2013-01-17 2018-12-17 Bayer Cropscience Ag Proceso para preparar 5-fluoro-1-metil-3-difluorometil-1h-pirazol- 4-carbaldehido.
EA028858B9 (ru) 2013-02-06 2018-06-29 Байер Кропсайенс Акциенгезельшафт Галогензамещенные производные пиразола в качестве средств борьбы с вредителями
RU2016131792A (ru) 2014-01-03 2018-02-06 Байер Энимэл Хельс ГмбХ Новые пиразолил-гетероариламиды в качестве средств для борьбы с вредителями
BR112016016397B1 (pt) 2014-01-24 2021-06-29 Bayer Cropscience Aktiengesellschaft Processo para preparar 1-alquil-3-difluorometil-5- fluoro-1h-pirazol-4-carbaldeídos ou os seus ésteres
CN106029668B (zh) 2014-02-20 2018-02-23 葛兰素史克知识产权第二有限公司 吡咯并[3,2]嘧啶衍生物作为人类干扰素诱导剂
MA40281B1 (fr) 2014-06-03 2018-11-30 Idorsia Pharmaceuticals Ltd Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
MX2017006302A (es) 2014-11-13 2018-02-16 Glaxosmithkline Biologicals Sa Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
WO2017093180A1 (de) 2015-12-01 2017-06-08 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
CR20180286A (es) 2015-12-03 2018-07-16 Glaxosmithkline Ip Dev Ltd Dinucleotidos de purina cíclicos como moduladores de sting
SI3440076T1 (sl) 2016-04-07 2022-09-30 Glaxosmithkline Intellectual Property Development Limited Heterociklični amidi uporabni kot proteinski modulatorji
BR112018070602A2 (pt) 2016-04-07 2019-02-05 Glaxosmithkline Ip Dev Ltd composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
MX2019001918A (es) 2016-08-15 2019-09-06 Bayer Cropscience Ag Derivados del heterociclo biciclico condensado como agentes de control de plagas.
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3554490B1 (en) 2016-12-16 2022-02-16 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising a t-type calcium channel blocker
EP3577099B1 (en) 2017-02-06 2024-01-24 Idorsia Pharmaceuticals Ltd A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
CN117430622B (zh) 2017-10-04 2025-12-19 拜耳公司 用作害虫防治剂的杂环化合物的衍生物
TW201927771A (zh) 2017-10-05 2019-07-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 可作為蛋白質調節劑之雜環醯胺及其使用方法
JP7291130B2 (ja) 2017-10-05 2023-06-14 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド インターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質
EP3765466B1 (de) 2018-03-12 2022-05-25 Bayer Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
WO2019201921A1 (de) 2018-04-20 2019-10-24 Bayer Aktiengesellschaft Heterocyclen-derivate als schädlingsbekämpfungsmittel
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
EP3901147B1 (en) 2019-01-25 2023-11-22 Beijing Scitech-MQ Pharmaceuticals Limited Acylamino bridged heterocyclic compound, and composition and application thereof
JP2022533194A (ja) 2019-05-16 2022-07-21 スティングセラ インコーポレイテッド ベンゾ［ｂ］［１，８］ナフチリジン酢酸誘導体および使用方法
EP3969438A1 (en) 2019-05-16 2022-03-23 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
AU2020409429A1 (en) 2019-12-18 2022-06-16 Ctxt Pty Ltd Compounds
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
CN112194620B (zh) * 2020-12-04 2021-02-26 苏州开元民生科技股份有限公司 一种2-乙基-4-氰基吡啶的制备方法
CN113563167B (zh) * 2021-07-16 2023-09-08 南通华祥医药科技有限公司 一种2-甲基-1-四氢萘酮的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3786063A (en) 1971-05-24 1974-01-15 Universal Oil Prod Co Thiazolethiosulfonates
DE2155360C3 (de) * 1971-11-08 1980-04-03 Cassella Ag, 6000 Frankfurt Verfahren zur Herstellung von Acylbernsteinsäuredialkylestern
CA1144937A (en) 1977-12-22 1983-04-19 Dke J.E. Helgstrand Aromatic derivatives, pharmaceutical compositions and methods for combatting virus infections
US4326058A (en) 1979-02-05 1982-04-20 Sumitomo Chemical Company, Limited Organo-phosphoric esters and their production and use
US4489077A (en) 1983-03-23 1984-12-18 Warner-Lambert Company 3-Isoxa-zolyl-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxides
US6174868B1 (en) 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
AU688344B2 (en) 1993-07-19 1998-03-12 Mitsubishi-Tokyo Pharmaceuticals, Inc. Hepatitis C virus proliferation inhibitor
ES2219457T3 (es) 1993-11-19 2004-12-01 PARKE, DAVIS & COMPANY Derivados de 5,6-dihidropironas como inhibidores de proteasa y agentes antiviricos.
US5840751A (en) 1993-11-19 1998-11-24 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
US6005103A (en) 1993-11-19 1999-12-21 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
US5504104A (en) 1993-11-19 1996-04-02 Warner-Lambert Company Tricyclic pyrone derivatives as protease inhibitors and antiviral agents
CZ291856B6 (cs) 1993-11-19 2003-06-18 Parke, Davis & Company 5,6-Dihydropyronové deriváty jako inhibitory proteázy a protivirová činidla a farmaceutické kompozice obsahující tyto deriváty
US5834506A (en) 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
AU773567B2 (en) 1998-09-11 2004-05-27 Warner-Lambert Company HIV protease inhibitors
US6512006B1 (en) 1999-12-09 2003-01-28 Warner-Lambert Company HIV protease inhibitors
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
DOP2003000641A (es) * 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
US7148226B2 (en) * 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
JP4372195B2 (ja) * 2004-08-18 2009-11-25 ファイザー・インク Ｃ型肝炎ウイルスｒｎａ依存性ｒｎａポリメラーゼの阻害剤、並びにそれを使用する組成物及び治療

Also Published As

Publication number Publication date
CN101538268B (zh) 2011-07-27
AU2005273619B2 (en) 2009-05-28
EA200700338A1 (ru) 2007-08-31
ES2361845T3 (es) 2011-06-22
NZ552874A (en) 2010-04-30
AP2313A (en) 2011-10-31
PE20060677A1 (es) 2006-08-11
MY146123A (en) 2012-06-29
PL1781662T3 (pl) 2011-08-31
UY29068A1 (es) 2006-03-31
TW200612898A (en) 2006-05-01
EP1781662B1 (en) 2011-04-20
TWI376379B (en) 2012-11-11
US20060122399A1 (en) 2006-06-08
IL180933A0 (en) 2007-07-04
IL180933A (en) 2011-08-31
CA2577525A1 (en) 2006-02-23
US7622605B2 (en) 2009-11-24
CR20110153A (es) 2011-04-26
JP2008509984A (ja) 2008-04-03
NL1029755C2 (nl) 2006-10-18
MX2007001527A (es) 2007-03-27
US20090281122A1 (en) 2009-11-12
CN101006092B (zh) 2013-04-17
EA012605B1 (ru) 2009-10-30
KR20070044057A (ko) 2007-04-26
ATE506364T1 (de) 2011-05-15
US20070015764A1 (en) 2007-01-18
ZA200700779B (en) 2008-11-26
US7151105B2 (en) 2006-12-19
DE602005027580D1 (de) 2011-06-01
EP1781662A1 (en) 2007-05-09
SV2007002202A (es) 2007-03-20
ECSP077264A (es) 2007-04-26
CY1111480T1 (el) 2015-08-05
US8268835B2 (en) 2012-09-18
CR8935A (es) 2007-07-24
GT200500221A (es) 2006-06-21
BRPI0514425A (pt) 2008-06-10
RS51794B (sr) 2011-12-31
WO2006018725A1 (en) 2006-02-23
HK1109617A1 (en) 2008-06-13
JP4372195B2 (ja) 2009-11-25
TNSN07066A1 (fr) 2008-06-02
HRP20110458T1 (hr) 2011-07-31
CN101538268A (zh) 2009-09-23
SI1781662T1 (sl) 2011-07-29
MA28803B1 (fr) 2007-08-01
UA88909C2 (ru) 2009-12-10
NI200700043A (es) 2008-01-02
CN101006092A (zh) 2007-07-25
IL192919A0 (en) 2009-02-11
AP2007003918A0 (en) 2007-02-28
HN2005000449A (es) 2009-10-30
GEP20094751B (en) 2009-08-10
DK1781662T3 (da) 2011-06-27
NO20071274L (no) 2007-05-14
GEP20115305B (en) 2011-10-10
KR100851178B1 (ko) 2008-08-08
NL1029755A1 (nl) 2006-02-21
AU2005273619A1 (en) 2006-02-23
CA2577525C (en) 2010-03-30
AR050699A1 (es) 2006-11-15

Similar Documents

Publication Publication Date Title
IL180933A0 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
AU2003224371A1 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
WO2007140200A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2007140254A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2007092888A3 (en) Hcv ns5b inhibitors
AP2406A (en) Macrocydic inhibitors of hepatitis C virus.
NL1025544A1 (nl) Remmers van rna-afhankelijk rna-polymerase van hepatitis-c-virus en preparaten en behandelingen waarbij ze worden gebruikt.
WO2004073599A3 (en) Inhibitors of hepatitis c virus, compositions and treatments using the same
SI1414441T1 (sl) Inhibitorji polimeraze virusa hepatitisa c, ki imajo heterobicikliäśno strukturo
IL219150A0 (en) Viral polymerase inhibitors and pharmaceutical compositions comprising thereof
IL198248A0 (en) Hepatitis c virus inhibitors and compositions comprising the same
AU2002252183A1 (en) Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
AU2003256619A8 (en) Thionucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
HUP0400726A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
EP1684787A4 (en) INHIBITORS OF HEPATITIS C VIRUS
WO2004007512A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
TW200745035A (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2007092645A3 (en) Novel hcv inhibitor combinations and methods
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
IL182583A0 (en) 4-methoxymethyl-pyrrolidine-2-carboxylic acid compounds and derivatives thereof as hepatitis c virus inhibitors
MX2010005226A (es) Inhibidores de ns5b de hcv de indolobenzazepina fusionados a ciclopropilo.
WO2005034850A3 (en) Cycloalkyl heterocycles for treating hepatitis c virus
EP1450809A4 (en) NUCLEOSIDES, THEIR PREPARATION AND USE AS AN INHIBITORS OF RNA VIRUS POLYMERASES
ZA200701674B (en) Vaccine composition against Hepatitis C virus
HUE026600T2 (hu) Készítmények és eljárások virális hepatitis kezelésére